one hundred eighty-six patients with advanced non-small-cell lung cancer were randomly assigned to treatment with combined 5-fluorouracil , doxorubicin , and mitomycin c ( fam ) or combined methotrexate , doxorubicin , cyclophosphamide , and lomustine ( macc ) .
C0025677
methotrexate
C0065473
macc